IL-20 in rheumatoid arthritis.

Abstract

Rheumatoid arthritis, a systemic autoimmune disease, causes chronic joint inflammation and bone destruction. Interleukin (IL)-20's association with this disease, and its expression and regulation has been extensively studied since 2006. Anti-IL-20 antibody has paved the way to clinical trials aimed at blocking the pathogenic actions of IL-20 in rheumatoid arthritis. This review focuses on current knowledge of IL-20's involvement in the pathogenesis of rheumatoid arthritis.

• Authors: Yu-Hsiang Hsu, Ming-Shi Chang
• Journal: Drug discovery today (Drug Discov Today) Vol. 22 Issue 6 Pg. 960-964 (06 2017) ISSN: 1878-5832 [Electronic] England
• PMID: 26297177 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies
• Interleukins
• interleukin 20

Topics

• Animals
• Antibodies (therapeutic use)
• Arthritis, Rheumatoid (drug therapy, immunology)
• Chondrocytes (immunology)
• Fibroblasts (immunology)
• Humans
• Interleukins (immunology)
• Osteoblasts (immunology)
• Osteoclasts (immunology)